GKOS logo

GLAUKOS CORP

GKOSNYSE
🏆 #783 by market capEarnings Oct 28US Equity
$181.45▲ $0.18 (+0.10%)
Market closed · at close
🔔
Track GKOS
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 0.1%
7d▲ 2.5%
14d▲ 9.4%
30d▲ 14.5%
ytd▲ 60.8%
1y▲ 135.9%
🏦Market Cap
$10.70B
Mid Cap
📈Revenue Growth (YoY)
41.5%
High Growth
📊Gross Margin
79.1%
High
💵FCF Margin
2.6%
Thin
⚖️P/S Ratio
17.4x
Expensive
Otter Score
68
Fair

Trading Snapshot

Day Range
$176.53 – $187.94
52-Week Range
$73.16 – $191.62
Volume (shares)
69,567
Avg Volume (shares)
—
Shares Outstanding
59.0M
Next Earnings
2026-10-28

Fundamentals Snapshot

Annual Revenue
$507M
Last Q Revenue
$186M
P/E Ratio
—
P/S Ratio
17.4x
EPS (TTM)
$-3.26
Dividend Yield
—
Dilution (1yr)
+3.5%
GKOS logo

GLAUKOS CORP

GKOS
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$507M▲ +32.3% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
77.5%▲ +2.7% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$87M▼ −29.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$54M▼ −20.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
57.5M▲ +3.5% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$49M▼ −$115M YoY
StockOtter · stockotter.space

About GLAUKOS CORP

Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
68/100

Analyst Ratings

ⓘ
Consensus
Buy
20 analysts
Strong Buy8
Buy10
Hold2
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

News unavailable.